Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : U.S. to begin distributing Regeneron's COVID-19 antibody therapy starting Tuesday

11/23/2020 | 02:25pm EST

Nov 23 (Reuters) - U.S. government will begin distributing Regeneron Pharmaceuticals Inc's newly authorized COVID-19 antibody combination therapy starting Tuesday, beginning with over 30,000 courses, a health official said during a media call on Monday.

The U.S. Food and Drug Administration on Saturday issued emergency use authorization for the antibody cocktail to be used for the treatment of mild to moderate COVID-19 in adults and children who are at high risk of progressing to severe COVID-19. (Reporting by Manojna Maddipatla in Bengaluru Editing by Chizu Nomiyama)


© Reuters 2020
All news about REGENERON PHARMACEUTICALS
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds
DJ
01/19REGENERON PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2020 Financia..
PR
01/19REGENERON PHARMACEUTICALS : Morgan Stanley Adjusts Regeneron Pharmaceuticals PT ..
MT
01/15REGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (fo..
AQ
01/13S&P closes higher with defensive sectors leading gains
RE
01/13Wall St gains steadily while impeachment hearings get underway
RE
01/13SECTOR UPDATE : Health Care Stocks Trading Lower Premarket Wednesday
MT
01/13REGENERON PHARMACEUTICALS : Benchmark Upgrades Regeneron Pharmaceuticals to Buy ..
MT
More news
Financials (USD)
Sales 2020 8 519 M - -
Net income 2020 3 191 M - -
Net cash 2020 5 478 M - -
P/E ratio 2020 19,1x
Yield 2020 -
Capitalization 56 760 M 56 760 M -
EV / Sales 2020 6,02x
EV / Sales 2021 4,43x
Nbr of Employees 8 314
Free-Float 83,1%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 654,96 $
Last Close Price 537,78 $
Spread / Highest target 47,5%
Spread / Average Target 21,8%
Spread / Lowest Target -7,03%
EPS Revisions
Managers and Directors
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Patrice Gilooly Senior VP-Quality Assurance & Operations
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS11.32%56 760
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
BEIGENE, LTD.44.94%34 148
GENMAB A/S7.31%28 292